Page 1

bioporto H1 2026 Interim Report January 1 - June 30 2026 " During the second quarter we continued to execute on our Forward Strategy and delivered strong underlying NGAL growth . We sharpened our strategic focus through the divestment of the antibody business and enabled an even clearer prioritization of our core NGAL platform . At the same time , we advanced our U.S. regulatory pathway for the adult segment following FDA feedback , supporting an expanded validation study and a stronger foundation for our planned 510 ( k ) submission . These steps reinforce a more focused organization and strengthen our long - term commercial opportunity in the U.S. AKI market . " H1 2026 Interim Report 1 a Carsten Buhl Chief Executive Officer